Biosimilars in rheumatology: current perspectives and lessons learnt
Authors:
- 18 August 2015
- journal article
- review article
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 11 (12) , 713-724
Abstract
Biosimilars, based on biopharmaceuticals approved by regulatory agencies that are no longer under patent protection, have efficacy and safety comparable to their reference products, and are a new therapeutic option to treat inflammatory diseases. Biosimilars must be distinguished from 'biomimics' or 'biocopies', which are marketed in some countries but have not been evaluated according to the stringent regulatory pathway used for biosimilars. CT-P13, based on infliximab, was the first biosimilar approved for the treatment of inflammatory diseases; however, some countries did not allow extrapolation of indications to all eight diseases for which the reference drug infliximab is approved. Antidrug antibodies can reduce drug levels and affect clinical efficacy, but although available data suggest that biosimilars and their reference products have comparable immunogenicity, this important property might differ between individual biopharmaceuticals. This Review discusses biosimilars already approved within the past 3 years to treat rheumatic diseases, as well as others that are currently under development. The main challenges posed by biosimilars are also addressed, such as the extrapolation of indications to diseases only studied for the reference drug, and the definition of strategies for adequate pharmacovigilance to monitor biosimilars after marketing approval.Keywords
This publication has 34 references indexed in Scilit:
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals of the Rheumatic Diseases, 2013
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals of the Rheumatic Diseases, 2013
- Rituximab biosimilarsExpert Opinion on Biological Therapy, 2013
- The role of biosimilars in the treatment of rheumatic diseasesAnnals of the Rheumatic Diseases, 2013
- Biosimilars in rheumatology: the wind of changeAnnals of the Rheumatic Diseases, 2013
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritisNature Reviews Rheumatology, 2013
- Meta-analysis/Systematic review Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysisArchives of Medical Science, 2013
- The advent of biosimilar therapies in rheumatology—“O Brave New World”Nature Reviews Rheumatology, 2012
- Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed Etanercept (Enbrel®)BioDrugs, 2012
- A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis RegistriesSeminars in Arthritis and Rheumatism, 2010